nbi-1065845
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
6
Phase 3
5
Phase 4
0
Earliest trial started Feb 21, 2022 (NCT05203341)
Timeline
Indications
Studied for
Mechanism of action
PSMB9 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07196501 | Phase 3 | Aug 18, 2025 | Neurocrine Biosciences |
| NCT06963021 | Phase 3 | May 30, 2025 | Neurocrine Biosciences |
| NCT06966401 | Phase 3 | Apr 16, 2025 | Neurocrine Biosciences |
| NCT06911112 | Phase 3 | Mar 31, 2025 | Neurocrine Biosciences |
| NCT06786624 | Phase 3 | Jan 22, 2025 | Neurocrine Biosciences |
| NCT05203341 | Phase 2 | Feb 21, 2022 | Neurocrine Biosciences |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Neurocrine Biosciences | For profit | 6 | 6 | 2 | 2022 |
1 organizations
Page 1 / 1